FOCUS:Focus On Coronary Unstable Syndromes

Inclusion criteria

• Subject either not of childbearing potential or is not pregnant and agrees to use contraceptive measure for the duration of the study
• Subjects presenting within 12 hours after the last episode of chest pain with:

• An accelerating pattern of anginal pain
• A prolonged or recurrent anginal pain at rest or with minimal effort AND
• Evidence of myocardial ischemia on ECG manifested by at least one of the following ECG criteria: - new persistent or transient ST-segment depression OR transient or reversible ST-segment elevation or new persistent or transient T-wave inversion OR Abnormal cardiac markers defined as: CK-MB greater than the upper limit of normal Troponin T or I level greater than the upper limit of normal.

Exclusion criteria

• Known or suspected pregnancy or actively breast-feeding
• Female of childbearing potential not using or planning to use a reliable method of contraception
• Treatment with Hormone Replacement Therapy at time of randomization
• Angina precipitated by obvious provoking factors
• Heart Failure defined as known ejection fraction less or equal to 40% or NYHA (New York Heart Association) class III pr IV
• Type I Diabetes Mellitus
• Type II diabetes requiring insulin therapy
• Hyperkaliemia
• Acute chronic inflammatory, collagen tissue disease, auto-immune disease or cancer and/or requiring the use of anti-inflammatory or anti-neoplastic agents at the time of randomization
• Use of a non-steriodal anti-inflammatory agent, coxibs, or anti-neoplasic agent within last 7 days
• Use of any oral or intra-venous steroidal agent in the last 7 days before study entry
• Uncontrolled hypertension
• Systolic pressure < 100 mmHg at randomization
• Likelihood of requiring treatment during the study period with drugs not permitted by the protocol
• Treatment with any investigational product or device in the last 4 weeks
• Previous participation into the trial
• History of hypersensitivity, allergy, or intolerance to Angiotensin-Converting Enzyme inhibitors.
• Severe cardiovascular diseases requiring urgent therapy
• Severe or co-morbid condition
• History of cancer not known to be disease free, with the exception of basal cell carcinoma of the skin
• Clinically important systemic disorder
• Impaired hepatic function
• Clinically important chronic or acute renal failure
• History of drug or alcohol abuse